Page last updated: 2024-08-07 15:59:27
Matrix metalloproteinase-9
A matrix metalloproteinase-9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P14780]
Synonyms
MMP-9;
EC 3.4.24.35;
92 kDa gelatinase;
92 kDa type IV collagenase;
Gelatinase B;
GELB
Research
Bioassay Publications (91)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (8.79) | 18.2507 |
| 2000's | 44 (48.35) | 29.6817 |
| 2010's | 32 (35.16) | 24.3611 |
| 2020's | 7 (7.69) | 2.80 |
Compounds (66)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| amentoflavone | Homo sapiens (human) | Kd | 2.1800 | 1 | 1 |
| MMP-9-IN-1 | Homo sapiens (human) | Kd | 2.1000 | 1 | 1 |
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.Bioorganic & medicinal chemistry, , Mar-15, Volume: 15, Issue:6, 2007
The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.Bioorganic & medicinal chemistry letters, , Nov-19, Volume: 11, Issue:22, 2001
Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.Bioorganic & medicinal chemistry letters, , Jan-22, Volume: 11, Issue:2, 2001
The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.Bioorganic & medicinal chemistry letters, , Jan-22, Volume: 11, Issue:2, 2001
The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.Bioorganic & medicinal chemistry letters, , Aug-20, Volume: 11, Issue:16, 2001
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.Journal of natural products, , 10-28, Volume: 85, Issue:10, 2022
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.Journal of medicinal chemistry, , 08-08, Volume: 62, Issue:15, 2019
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.Journal of medicinal chemistry, , 01-24, Volume: 62, Issue:2, 2019
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential TreatJournal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Jan-03, Volume: 45, Issue:1, 2002
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.Journal of medicinal chemistry, , Aug-02, Volume: 44, Issue:16, 2001
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.Bioorganic & medicinal chemistry letters, , Feb-12, Volume: 11, Issue:3, 2001
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 9, Issue:12, 1999
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.Journal of medicinal chemistry, , 06-23, Volume: 65, Issue:12, 2022
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
[no title available]Journal of medicinal chemistry, , 12-10, Volume: 63, Issue:23, 2020
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.Bioorganic & medicinal chemistry letters, , May-01, Volume: 26, Issue:9, 2016
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.Journal of medicinal chemistry, , Jul-14, Volume: 54, Issue:13, 2011
The evaluation of inhibitive effectiveness of the tumour necrosis factor-α converting enzyme selective inhibitors by HPLC.Journal of enzyme inhibition and medicinal chemistry, , Volume: 26, Issue:2, 2011
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.Bioorganic & medicinal chemistry, , Sep-15, Volume: 16, Issue:18, 2008
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.Bioorganic & medicinal chemistry, , Jul-15, Volume: 15, Issue:14, 2007
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.The Journal of biological chemistry, , Sep-21, Volume: 282, Issue:38, 2007
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.Journal of medicinal chemistry, , Jan-26, Volume: 49, Issue:2, 2006
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.Bioorganic & medicinal chemistry letters, , Jan-05, Volume: 14, Issue:1, 2004
Matrix metalloproteinase inhibitors: a structure-activity study.Journal of medicinal chemistry, , Jan-15, Volume: 41, Issue:2, 1998
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.Bioorganic & medicinal chemistry, , 05-15, Volume: 27, Issue:10, 2019
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).Bioorganic & medicinal chemistry, , 01-01, Volume: 27, Issue:1, 2019
Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 28, Issue:14, 2018
Discovery of dehydroabietic acid sulfonamide based derivatives as selective matrix metalloproteinases inactivators that inhibit cell migration and proliferation.European journal of medicinal chemistry, , Sep-29, Volume: 138, 2017
Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.Journal of medicinal chemistry, , Jun-11, Volume: 52, Issue:11, 2009
Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.Journal of medicinal chemistry, , Aug-01, Volume: 40, Issue:16, 1997
[no title available]European journal of medicinal chemistry, , Nov-01, Volume: 181, 2019
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 15, Issue:5, 2005
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Jan-03, Volume: 45, Issue:1, 2002
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.Bioorganic & medicinal chemistry letters, , Feb-12, Volume: 11, Issue:3, 2001
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Nov-04, Volume: 42, Issue:22, 1999
Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.Journal of medicinal chemistry, , 01-26, Volume: 60, Issue:2, 2017
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.Bioorganic & medicinal chemistry, , Oct-01, Volume: 22, Issue:19, 2014
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.Journal of medicinal chemistry, , Nov-13, Volume: 57, Issue:21, 2014
Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.Journal of medicinal chemistry, , Jun-11, Volume: 52, Issue:11, 2009
Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.Journal of medicinal chemistry, , Oct-20, Volume: 48, Issue:21, 2005
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 15, Issue:4, 2005
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.European journal of medicinal chemistry, , Oct-15, Volume: 222, 2021
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.Bioorganic & medicinal chemistry, , Jul-01, Volume: 20, Issue:13, 2012
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.Bioorganic & medicinal chemistry letters, , Jan-03, Volume: 15, Issue:1, 2005
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.Journal of medicinal chemistry, , Jul-31, Volume: 46, Issue:16, 2003
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.Bioorganic & medicinal chemistry letters, , Feb-26, Volume: 11, Issue:4, 2001
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Identification of potent and selective TACE inhibitors via the S1 pocket.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 17, Issue:1, 2007
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.Journal of medicinal chemistry, , Nov-07, Volume: 45, Issue:23, 2002
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Jan-03, Volume: 45, Issue:1, 2002
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.Bioorganic & medicinal chemistry, , Jul-01, Volume: 23, Issue:13, 2015
Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.Journal of medicinal chemistry, , Sep-12, Volume: 56, Issue:17, 2013
A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.Journal of medicinal chemistry, , May-24, Volume: 55, Issue:10, 2012
Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.Journal of medicinal chemistry, , Aug-01, Volume: 40, Issue:16, 1997
Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.Journal of medicinal chemistry, , Jun-11, Volume: 52, Issue:11, 2009
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.Bioorganic & medicinal chemistry letters, , Jun-18, Volume: 11, Issue:12, 2001
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing.Journal of medicinal chemistry, , 10-11, Volume: 61, Issue:19, 2018
Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.ACS medicinal chemistry letters, , Jun-14, Volume: 3, Issue:6, 2012
Sulfonate-containing thiiranes as selective gelatinase inhibitors.ACS medicinal chemistry letters, , Feb-10, Volume: 2, Issue:2, 2011
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.Bioorganic & medicinal chemistry, , Mar-15, Volume: 15, Issue:6, 2007
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Jan-27, Volume: 43, Issue:2, 2000
MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.Bioorganic & medicinal chemistry letters, , May-15, Volume: 21, Issue:10, 2011
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.Journal of medicinal chemistry, , Sep-23, Volume: 53, Issue:18, 2010
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.Bioorganic & medicinal chemistry letters, , Aug-20, Volume: 11, Issue:16, 2001
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.Bioorganic & medicinal chemistry letters, , May-19, Volume: 8, Issue:10, 1998
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
Sulphonamides: Deserving class as MMP inhibitors?European journal of medicinal chemistry, , Volume: 60, 2013
Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 15, Issue:5, 2005
Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.Journal of medicinal chemistry, , May-20, Volume: 42, Issue:10, 1999
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.Journal of medicinal chemistry, , Feb-12, Volume: 41, Issue:4, 1998
Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.European journal of medicinal chemistry, , Jan-27, Volume: 108, 2016
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.Journal of medicinal chemistry, , Oct-22, Volume: 52, Issue:20, 2009
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 15, Issue:5, 2005
Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 18, Issue:5, 2008
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.Journal of medicinal chemistry, , Feb-22, Volume: 50, Issue:4, 2007
Enables
This protein enables 9 target(s):
| Target | Category | Definition |
|---|
| endopeptidase activity | molecular function | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain. [http://merops.sanger.ac.uk/about/glossary.htm#ENDOPEPTIDASE] |
| metalloendopeptidase activity | molecular function | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#ENDOPEPTIDASE] |
| serine-type endopeptidase activity | molecular function | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine). [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| collagen binding | molecular function | Binding to collagen, a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. Collagen is highly enriched in glycine (some regions are 33% glycine) and proline, occurring predominantly as 3-hydroxyproline (about 20%). [GOC:ai, ISBN:0198506732] |
| peptidase activity | molecular function | Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid. [GOC:jl, ISBN:0815332181] |
| metallopeptidase activity | molecular function | Catalysis of the hydrolysis of peptide bonds by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE] |
| zinc ion binding | molecular function | Binding to a zinc ion (Zn). [GOC:ai] |
| identical protein binding | molecular function | Binding to an identical protein or proteins. [GOC:jl] |
Located In
This protein is located in 6 target(s):
| Target | Category | Definition |
|---|
| extracellular region | cellular component | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. [GOC:go_curators] |
| extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
| collagen-containing extracellular matrix | cellular component | An extracellular matrix consisting mainly of proteins (especially collagen) and glycosaminoglycans (mostly as proteoglycans) that provides not only essential physical scaffolding for the cellular constituents but can also initiate crucial biochemical and biomechanical cues required for tissue morphogenesis, differentiation and homeostasis. The components are secreted by cells in the vicinity and form a sheet underlying or overlying cells such as endothelial and epithelial cells. [GOC:BHF, GOC:rph, PMID:21123617] |
| extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
| tertiary granule lumen | cellular component | Any membrane-enclosed lumen that is part of a tertiary granule. [GO_REF:0000064, GOC:TermGenie, PMID:23650620] |
| ficolin-1-rich granule lumen | cellular component | Any membrane-enclosed lumen that is part of a ficolin-1-rich granule. [GO_REF:0000064, GOC:TermGenie, PMID:23650620] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
Involved In
This protein is involved in 30 target(s):
| Target | Category | Definition |
|---|
| skeletal system development | biological process | The process whose specific outcome is the progression of the skeleton over time, from its formation to the mature structure. The skeleton is the bony framework of the body in vertebrates (endoskeleton) or the hard outer envelope of insects (exoskeleton or dermoskeleton). [GOC:dph, GOC:jid, GOC:tb] |
| positive regulation of protein phosphorylation | biological process | Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein. [GOC:hjd] |
| proteolysis | biological process | The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds. [GOC:bf, GOC:mah] |
| apoptotic process | biological process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. [GOC:cjm, GOC:dhl, GOC:ecd, GOC:go_curators, GOC:mtg_apoptosis, GOC:tb, ISBN:0198506732, PMID:18846107, PMID:21494263] |
| embryo implantation | biological process | Attachment of the blastocyst to the uterine lining. [GOC:isa_complete, http://www.medterms.com] |
| cell migration | biological process | The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues. [GOC:cjm, GOC:dph, GOC:ems, GOC:pf, Wikipedia:Cell_migration] |
| extracellular matrix disassembly | biological process | A process that results in the breakdown of the extracellular matrix. [GOC:jid] |
| macrophage differentiation | biological process | The process in which a relatively unspecialized monocyte acquires the specialized features of a macrophage. [GOC:add, ISBN:0781735149] |
| collagen catabolic process | biological process | The proteolytic chemical reactions and pathways resulting in the breakdown of collagen in the extracellular matrix, usually carried out by proteases secreted by nearby cells. [GOC:mah, ISBN:0815316194] |
| cellular response to reactive oxygen species | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reactive oxygen species stimulus. Reactive oxygen species include singlet oxygen, superoxide, and oxygen free radicals. [GOC:mah] |
| endodermal cell differentiation | biological process | The process in which a relatively unspecialized cell acquires the specialized features of an endoderm cell, a cell of the inner of the three germ layers of the embryo. [CL:0000223, GOC:yaf, PMID:17624332] |
| positive regulation of apoptotic process | biological process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis] |
| negative regulation of apoptotic process | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis] |
| positive regulation of DNA binding | biological process | Any process that increases the frequency, rate or extent of DNA binding. DNA binding is any process in which a gene product interacts selectively with DNA (deoxyribonucleic acid). [GOC:dph, GOC:jl, GOC:tb] |
| positive regulation of epidermal growth factor receptor signaling pathway | biological process | Any process that activates or increases the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity. [GOC:go_curators] |
| ephrin receptor signaling pathway | biological process | The series of molecular signals initiated by ephrin binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:ceb] |
| positive regulation of keratinocyte migration | biological process | Any process that activates or increases the frequency, rate or extent of keratinocyte migration. [GOC:ai] |
| cellular response to lipopolysaccharide | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. [GOC:mah] |
| cellular response to cadmium ion | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cadmium (Cd) ion stimulus. [GOC:mah] |
| cellular response to UV-A | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-A radiation stimulus. UV-A radiation (UV-A light) spans the wavelengths 315 to 400 nm. [GOC:mah] |
| positive regulation of release of cytochrome c from mitochondria | biological process | Any process that increases the rate, frequency or extent of release of cytochrome c from mitochondria, the process in which cytochrome c is enabled to move from the mitochondrial intermembrane space into the cytosol, which is an early step in apoptosis and leads to caspase activation. [GOC:BHF, GOC:dph, GOC:mtg_apoptosis, GOC:tb] |
| regulation of neuroinflammatory response | biological process | Any process that modulates the frequency, rate or extent of neuroinflammatory response. [GOC:aruk, GOC:bc, PMID:10981966, PMID:11099416, PMID:18164423] |
| positive regulation of receptor binding | biological process | Any process that activates or increases the frequency, rate or extent of a protein or other molecule binding to a receptor. [GOC:signaling, GOC:TermGenie] |
| response to amyloid-beta | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a amyloid-beta stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:23555824] |
| positive regulation of vascular associated smooth muscle cell proliferation | biological process | Any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell proliferation. [GO_REF:0000058, GOC:TermGenie, PMID:23246467] |
| negative regulation of epithelial cell differentiation involved in kidney development | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of epithelial cell differentiation involved in kidney development. [GOC:mtg_kidney_jan10, GOC:yaf] |
| negative regulation of intrinsic apoptotic signaling pathway | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway. [GOC:mtg_apoptosis] |
| negative regulation of cation channel activity | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of cation channel activity. [GOC:BHF] |
| negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of cysteine-type endopeptidase activity involved in apoptotic signaling pathway. [GOC:mtg_apoptosis] |
| extracellular matrix organization | biological process | A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an extracellular matrix. [GOC:mah] |